317 related articles for article (PubMed ID: 24863045)
1. Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.
Imeri F; Fallegger D; Zivkovic A; Schwalm S; Enzmann G; Blankenbach K; Meyer zu Heringdorf D; Homann T; Kleuser B; Pfeilschifter J; Engelhardt B; Stark H; Huwiler A
Neuropharmacology; 2014 Oct; 85():314-27. PubMed ID: 24863045
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis: Resistance to FTY720 but not ST-968 treatments.
Imeri F; Schwalm S; Lyck R; Zivkovic A; Stark H; Engelhardt B; Pfeilschifter J; Huwiler A
Neuropharmacology; 2016 Jun; 105():341-350. PubMed ID: 26808312
[TBL] [Abstract][Full Text] [Related]
3. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.
Kataoka H; Sugahara K; Shimano K; Teshima K; Koyama M; Fukunari A; Chiba K
Cell Mol Immunol; 2005 Dec; 2(6):439-48. PubMed ID: 16426494
[TBL] [Abstract][Full Text] [Related]
4. Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis.
Jin J; Hu J; Zhou W; Wang X; Xiao Q; Xue N; Yin D; Chen X
Biochem Pharmacol; 2014 Jul; 90(1):50-61. PubMed ID: 24780445
[TBL] [Abstract][Full Text] [Related]
5. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
6. FTY720 and two novel butterfly derivatives exert a general anti-inflammatory potential by reducing immune cell adhesion to endothelial cells through activation of S1P(3) and phosphoinositide 3-kinase.
Imeri F; Blanchard O; Jenni A; Schwalm S; Wünsche C; Zivkovic A; Stark H; Pfeilschifter J; Huwiler A
Naunyn Schmiedebergs Arch Pharmacol; 2015 Dec; 388(12):1283-92. PubMed ID: 26267293
[TBL] [Abstract][Full Text] [Related]
7. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
8. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.
Papadopoulos D; Rundle J; Patel R; Marshall I; Stretton J; Eaton R; Richardson JC; Gonzalez MI; Philpott KL; Reynolds R
J Neurosci Res; 2010 Feb; 88(2):346-59. PubMed ID: 19658199
[TBL] [Abstract][Full Text] [Related]
9. Morpholino Analogues of Fingolimod as Novel and Selective S1P
Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
[TBL] [Abstract][Full Text] [Related]
11. FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Ntranos A; Hall O; Robinson DP; Grishkan IV; Schott JT; Tosi DM; Klein SL; Calabresi PA; Gocke AR
J Neuroimmunol; 2014 May; 270(1-2):13-21. PubMed ID: 24680062
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.
Chiba K; Kataoka H; Seki N; Shimano K; Koyama M; Fukunari A; Sugahara K; Sugita T
Int Immunopharmacol; 2011 Mar; 11(3):366-72. PubMed ID: 20955831
[TBL] [Abstract][Full Text] [Related]
13. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
14. Novel compounds with dual S1P receptor agonist and histamine H
Imeri F; Stepanovska Tanturovska B; Zivkovic A; Enzmann G; Schwalm S; Pfeilschifter J; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
Neuropharmacology; 2021 Mar; 186():108464. PubMed ID: 33460688
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
16. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
García-Merino JA; Sánchez AJ
Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
[TBL] [Abstract][Full Text] [Related]
17. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
18. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
Schmid G; Guba M; Ischenko I; Papyan A; Joka M; Schrepfer S; Bruns CJ; Jauch KW; Heeschen C; Graeb C
J Cell Biochem; 2007 May; 101(1):259-70. PubMed ID: 17203465
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
Dudek SM; Camp SM; Chiang ET; Singleton PA; Usatyuk PV; Zhao Y; Natarajan V; Garcia JG
Cell Signal; 2007 Aug; 19(8):1754-64. PubMed ID: 17475445
[TBL] [Abstract][Full Text] [Related]
20. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
